Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Tag: chemotherapy
All
Latest
All
Latest
Sensorion, Cochlear Ltd Start Pilot Study for SENS-401
Sensorion and Cochlear Limited (ASX:COH), announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401 (Arazasetron) in patients scheduled for cochlear implantation.
All
Latest
Cisplatin Dosing, Delivery May Affect Hearing Loss
The study establishes “the first benchmarks for the prevalence of hearing loss,” and reveals that the risk of hearing loss is affected not only by how much drug is given, but by how that drug is delivered—dosing schedules, complementary treatments, and more.
USC Researchers Produce Sensory Hearing Cells
To achieve reprogramming, the scientists exposed fibroblasts and supporting cells to a cocktail of four transcription factors, which are molecules that help convey the instructions encoded in DNA. The scientists identified this cocktail by testing various combinations of 16 transcription factors that were highly active in the hair cells of newborn mice.
Read More
Fennec Announces FDA Filing Acceptance for Ototoxicity Drug, Pedmark
PEDMARK is said to be an investigational drug for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to <18 years of age with localized, non-metastatic, solid tumors.
Read More
Education May Help Cancer Survivors Cope with Hearing Loss
Researchers involved with a qualitative study published in Cancer concluded that clinicians play...
Read More
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Otonomy Announces Upcoming Presentations at 42nd ARO MidWinter Meeting
“Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss, and otoprotection,” said Kathie Bishop, PhD, chief scientific officer of Otonomy.
Read More
University of Connecticut Researchers Find Protein Connected with Hearing Loss
UConn otolaryngologist Kourosh Parham and his colleagues report in “Hearing Research” that levels of prestin, a protein found only in cells in the inner ear, rise sharply when those cells are damaged and start to die.
Read More
New Research Highlights Outcomes of Ida Institute’s Methods and Tools
Since 2016, the Ida Institute Research Committee has awarded research grants to projects that investigate the outcomes of using Ida Institute methods and tools and develop evidence to show the effect of person-centered hearing care.
Read More
Webinar on Pediatric Chemo-Induced Hearing Loss to Be Held September 13
This half-day event follows the Food and Drug Administration’s (FDA) model for externally-led Patient Focused Drug Development meetings and serves to inform the agency’s regulatory decision-making in pediatric oncology.
Read More
Sensorion Receives Approval for SENS-401 Phase 2 Clinical Trial
The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the US, Canada, Israel, and Turkey, and enroll approximately 260 patients.
Read More
Sodium Thiosulfate May Help Reduce Cisplatin-Related Hearing Loss, New Study Says
The study showed that STS administered six hours after Cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Read More
Fennec Pharmaceuticals’ Cisplatin-Ototoxicity Treatment Given Breakthrough Therapy Designation
According to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.
Read More
Otomagnetics Reduces Cisplatin-Related Hearing Loss in Mice, New Study Shows
Using a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%.
Read More
Sensorion Receives Orphan Drug Designation for Chemotherapy-Induced, Hearing Loss Treatment
The drug is a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients.
Read More
Sound Pharmaceuticals Receives Award for Drug Used to Treat Hearing Loss in Cystic Fibrosis Patients
Sound Pharmaceuticals announced that the company has been awarded up to $1.6 million for their development of a drug used to treat ototoxicity in patients with cystic fibrosis.
Read More